566 related articles for article (PubMed ID: 15767638)
1. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
[TBL] [Abstract][Full Text] [Related]
2. Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Cancer and Leukemia Group B.
Hurd DD; Peters WP
J Natl Cancer Inst Monogr; 1995; (19):41-4. PubMed ID: 7577204
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
Zander AR; Kröger N; Schmoor C; Krüger W; Möbus V; Frickhofen N; Metzner B; Schultze W; Berdel WE; Koenigsmann M; Thiel E; Wandt H; Possinger K; Trümper L; Kreienberg R; Carstensen M; Schmidt EH; Jänicke F; Schumacher M; Jonat W
J Clin Oncol; 2004 Jun; 22(12):2273-83. PubMed ID: 15111618
[TBL] [Abstract][Full Text] [Related]
4. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
5. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
[TBL] [Abstract][Full Text] [Related]
8. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
[TBL] [Abstract][Full Text] [Related]
9. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
[TBL] [Abstract][Full Text] [Related]
10. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
[TBL] [Abstract][Full Text] [Related]
11. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
[TBL] [Abstract][Full Text] [Related]
13. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Moebus V; Jackisch C; Lueck HJ; du Bois A; Thomssen C; Kurbacher C; Kuhn W; Nitz U; Schneeweiss A; Huober J; Harbeck N; von Minckwitz G; Runnebaum IB; Hinke A; Kreienberg R; Konecny GE; Untch M
J Clin Oncol; 2010 Jun; 28(17):2874-80. PubMed ID: 20458045
[TBL] [Abstract][Full Text] [Related]
14. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
[TBL] [Abstract][Full Text] [Related]
15. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Petros WP; Broadwater G; Berry D; Jones RB; Vredenburgh JJ; Gilbert CJ; Gibbs JP; Colvin OM; Peters WP
Clin Cancer Res; 2002 Mar; 8(3):698-705. PubMed ID: 11895898
[TBL] [Abstract][Full Text] [Related]
16. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
[TBL] [Abstract][Full Text] [Related]
17. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
[TBL] [Abstract][Full Text] [Related]
18. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment.
Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G
Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy (CTM) for breast cancer.
Damon LE; Wolf JL; Rugo HS; Gold E; Zander AR; Cassidy M; Cecchi G; Cohen N; Irwin D; Tracy M; Ries CA; Linker CA
Bone Marrow Transplant; 2000 Aug; 26(3):257-68. PubMed ID: 10967563
[TBL] [Abstract][Full Text] [Related]
20. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study.
Stemmer SM; Rizel S; Hardan I; Adamo A; Neumann A; Goffman J; Brenner HJ; Pfeffer MR
J Clin Oncol; 2003 Jul; 21(14):2713-8. PubMed ID: 12860949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
